Khiron Life Sciences closes $12.3 million equity financing

1 minute read
08 July 2021

On July 8, 2021, Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced that it had closed its previously announced offering to US institutional investors of units of the Company for aggregate gross proceeds of $12,345,750. A.G.P./Alliance Global Partners and ATB Capital Markets Inc. acted as placement agents for the offering.

The Company also filed a prospectus supplement in Canada to its existing Canadian base shelf prospectus filed with the securities regulatory authority in each of the provinces and territories of Canada to qualify the common shares issued in the offering, the warrants and the common shares issuable upon exercise of the warrants.

Gowling WLG was counsel to Khiron in this transaction with a team that included Peter Simeon, Jacob Cawker, Tara Amiri and Howard Xin.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.